Prot #RMC-4630-02: A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib

Project: Research project

Project Details

Effective start/end date7/7/207/7/23


  • PPD Investigator Services, LLC (Prot #RMC-4630-02)
  • Revolution Medicines, Inc. (Prot #RMC-4630-02)